COMPANY PROFILE // THE 014 REPORT
Medicus Pharma Ltd.
MDCX (Nasdaq) · MDCXW (Nasdaq)
Assembled from 2 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-11-19 and 3 more times (last 24 months).
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-06-05 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Medicus Pharma Ltd. is an SEC-registered operating company in pharmaceutical preparations, incorporated in Ontario, Canada, based in W. Conshohocken, PA; listed as MDCX (Nasdaq), MDCXW (Nasdaq).[source] It has filed 151 documents with the SEC in the last 12 months; the latest is Form 424B3, filed 2026-11-19.[source] Its largest institutional holders on 13F filings are Interchange Capital Partners, LLC, JANE STREET GROUP, LLC, XTX Topco Ltd (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 4.01 filed; 8-K Item 3.01 filed.[source]
- red0
- amber2
- info0
- Interchange Capital Partners, LLC$718K
- JANE STREET GROUP, LLC$149K
- XTX Topco Ltd$109K
- Sterling Investment Advisors, Ltd.$45K
- COMMONWEALTH EQUITY SERVICES, LLC$23K
- May Hill Capital, LLC$23K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP$14K
- STIFEL FINANCIAL CORP$13K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Bokhari Raza · Chief Executive Officer (Director,Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Bonner Carolyn F. · President and CFO (Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Brennan Edward J. · Chief Scientific Officer (Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Mehmud Faisal · Chief Medical Officer (Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Quinlan James P. · Chief Financial Officer (Officer) · latest Form 4 2025-08-14 · filing · LinkedIn search
- Smith Andrew Alasdair · Chief Operating Officer (Officer) · latest Form 4 2025-12-18 · filing · LinkedIn search
- Ashton William · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- Ciaruffoli Robert J. · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- FISHMAN BARRY · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- Kaiser Larry · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- MAHAFFY PATRICK J · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
- May Sara R. · Director · latest Form 4 2025-12-18 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Bennett Jones LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-01-30
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001997296 | source |
| EIN | 98-1778211 | source |
| Business address (SEC) | 300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN, PA, 19428 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (10)
- GENERATION LIFE · IRS-registered organization
- TEMPLETON FOUNDATION INC · IRS-registered organization
- THE PAPAL FOUNDATION · IRS-registered organization
- THE JAMIE & LISA MAGUIRE FAMILY FOUNDATION · IRS-registered organization
- TRANSCELERATE BIOPHARMA INC · IRS-registered organization
- JOHN TEMPLETON FOUNDATION · IRS-registered organization
- COBBS CREEK RESTORATION AND COMMUNITY FOUNDATION · IRS-registered organization
- ASM GLOBAL ACTS FOUNDATION · IRS-registered organization
- CHRIS AND ELLEN MAGUIRE FOUNDATION · IRS-registered organization
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-19 filing 424B3 · SEC EDGAR
- 2026-11-19 filing 8-K items 3.01,7.01,8.01,9.01 · SEC EDGAR
- 2026-11-17 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-11-16 filing 424B3 · SEC EDGAR
- 2026-11-16 filing 8-K items 1.01,3.02,3.03,8.01,9.01 · SEC EDGAR
- 2026-11-16 filing 424B5 · SEC EDGAR
- 2026-11-09 filing 425 · SEC EDGAR
- 2026-11-06 filing 425 · SEC EDGAR
- 2026-11-06 filing 424B3 · SEC EDGAR
- 2026-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-04 filing 425 · SEC EDGAR
- 2026-10-30 filing Proxy statement · SEC EDGAR
- 2026-10-26 filing 424B3 · SEC EDGAR
- 2026-10-23 filing 8-K items 3.01,8.01,9.01 · SEC EDGAR
- 2026-10-19 filing PRE 14A · SEC EDGAR
- 2026-10-16 filing 424B3 · SEC EDGAR
- 2026-10-16 filing 8-K items 3.03,5.03,9.01 · SEC EDGAR
- 2026-10-07 filing 424B3 · SEC EDGAR
- 2026-10-07 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-09-14 filing SCHEDULE 13D · SEC EDGAR
- 2026-09-14 filing 424B3 · SEC EDGAR
- 2026-09-14 filing 8-K items 1.02,9.01 · SEC EDGAR
- 2026-09-11 filing 8-K items 3.02,9.01 · SEC EDGAR
- 2026-09-03 filing 424B3 · SEC EDGAR
- 2026-09-03 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-08-13 filing 424B3 · SEC EDGAR
- 2026-08-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-06-04 filing 424B3 · SEC EDGAR
- 2026-06-04 filing 8-K items 5.07,9.01 · SEC EDGAR
170 earlier entries
- 2026-05-28 filing 424B3
- 2026-05-27 filing 8-K items 1.01,2.03,3.01,9.01
- 2026-05-14 filing 424B3
- 2026-05-14 filing Quarterly report (10-Q)
- 2026-05-04 filing ARS
- 2026-05-04 filing Proxy statement
- 2026-04-30 filing 424B3
- 2026-04-29 filing 10-K/A
- 2026-04-27 filing 424B3
- 2026-04-24 filing 8-K items 1.01,3.01,9.01
- 2026-04-23 filing 424B3
- 2026-04-21 filing PRE 14A
- 2026-03-27 filing EFFECT
- 2026-03-27 filing EFFECT
- 2026-03-27 filing EFFECT
- 2026-03-25 filing POS AM
- 2026-03-25 filing POS AM
- 2026-03-25 filing POS AM
- 2026-03-25 filing 424B3
- 2026-03-25 filing 424B3
- 2026-03-25 filing 424B3
- 2026-03-25 filing 424B3
- 2026-03-25 filing Annual report (10-K)
- 2026-03-06 filing 424B3
- 2026-03-06 filing 424B3
- 2026-03-06 filing 424B3
- 2026-03-06 filing 424B3
- 2026-03-06 filing 253G2
- 2026-03-06 filing 8-K items 3.02,9.01
- 2026-02-04 filing EFFECT
- 2026-01-30 filing CORRESP
- 2026-01-30 filing S-3
- 2026-01-15 filing UPLOAD
- 2026-01-12 filing DRS
- 2026-01-02 filing 424B5
- 2025-12-31 filing EFFECT
- 2025-12-30 filing 424B3
- 2025-12-30 filing 424B3
- 2025-12-30 filing 424B3
- 2025-12-30 filing 424B3
- 2025-12-30 filing 253G2
- 2025-12-30 filing 424B3
- 2025-12-30 filing 424B3
- 2025-12-30 filing 8-K items 1.01,9.01
- 2025-12-30 filing S-3
- 2025-12-29 filing CORRESP
- 2025-12-10 filing DRS
- 2025-12-08 filing 253G2
- 2025-12-08 filing 424B3
- 2025-12-08 filing 424B3
- 2025-12-08 filing 424B3
- 2025-12-08 filing 424B3
- 2025-12-08 filing 424B3
- 2025-12-08 filing 424B3
- 2025-12-08 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-12-05 filing 424B3
- 2025-12-04 filing EFFECT
- 2025-12-02 filing CORRESP
- 2025-12-01 filing 253G2
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 officer change 8-K items 5.02,7.01,9.01
- 2025-11-19 filing Registration (S-1)
- 2025-11-17 filing 424B3
- 2025-11-17 filing 424B3
- 2025-11-17 filing 424B3
- 2025-11-17 filing 424B3
- 2025-11-17 filing 424B3
- 2025-11-17 filing 253G2
- 2025-11-14 filing EFFECT
- 2025-11-14 filing EFFECT
- 2025-11-14 filing 8-K items 8.01,9.01
- 2025-11-14 filing S-8
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-10-17 filing 424B3
- 2025-10-17 filing 424B3
- 2025-10-17 filing 253G2
- 2025-10-17 filing 424B3
- 2025-10-17 filing 8-K items 3.02,9.01
- 2025-09-29 filing Registration (S-1)
- 2025-09-29 filing Registration (S-1)
- 2025-09-19 filing DRS
- 2025-09-18 filing 424B3
- 2025-09-18 filing 424B3
- 2025-09-18 filing 253G2
- 2025-09-18 filing 424B3
- 2025-09-18 filing 8-K items 1.01,2.03,8.01,9.01
- 2025-09-15 filing 424B3
- 2025-09-15 filing 424B3
- 2025-09-15 filing 253G2
- 2025-09-15 filing 424B3
- 2025-09-12 officer change 8-K items 5.02
- 2025-09-11 filing DRS
- 2025-09-08 insider First Form 3/4/5 on record for MAHAFFY PATRICK J (Director)
- 2025-09-02 filing 424B3
- 2025-09-02 filing 424B3
- 2025-09-02 filing 424B3
- 2025-09-02 filing 253G2
- 2025-09-02 officer change 8-K items 2.01,3.02,5.02,8.01,9.01
- 2025-08-22 filing 424B3
- 2025-08-22 filing 424B3
- 2025-08-22 filing 253G2
- 2025-08-22 filing 424B3
- 2025-08-22 filing 8-K items 3.02,8.01,9.01
- 2025-08-12 filing 424B3
- 2025-08-12 filing 424B3
- 2025-08-12 filing 253G2
- 2025-08-12 filing 424B3
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-06 filing 3/A
- 2025-08-04 filing 8-K items 8.01,9.01
- 2025-07-31 insider First Form 3/4/5 on record for Rodgers Cathy McMorris (Director)
- 2025-07-30 filing 8-K items 8.01
- 2025-07-24 insider First Form 3/4/5 on record for Bokhari Raza (Chief Executive Officer)
- 2025-07-24 insider First Form 3/4/5 on record for Bonner Carolyn F. (President and CFO)
- 2025-07-24 insider First Form 3/4/5 on record for Brennan Edward J. (Chief Scientific Officer)
- 2025-07-24 insider First Form 3/4/5 on record for Quinlan James P. (Chief Financial Officer)
- 2025-07-24 insider First Form 3/4/5 on record for Ashton William (Director)
- 2025-07-24 insider First Form 3/4/5 on record for Ciaruffoli Robert J. (Director)
- 2025-07-24 insider First Form 3/4/5 on record for FISHMAN BARRY (Director)
- 2025-07-24 insider First Form 3/4/5 on record for Kaiser Larry (Director)
- 2025-07-24 insider First Form 3/4/5 on record for May Sara R. (Director)
- 2025-07-24 insider First Form 3/4/5 on record for Raju Ajay (Director)
- 2025-07-23 filing 424B3
- 2025-07-23 filing 424B3
- 2025-07-23 filing 253G2
- 2025-07-23 filing 424B3
- 2025-07-23 filing 8-K items 5.07,8.01,9.01
- 2025-07-14 filing 424B3
- 2025-07-14 filing 424B3
- 2025-07-14 filing 424B3
- 2025-07-14 filing 253G2
- 2025-07-14 filing 8-K items 1.01,3.02,9.01
- 2025-07-03 filing 424B3
- 2025-07-03 filing 424B3
- 2025-07-03 filing 253G2
- 2025-07-03 filing 424B3
- 2025-07-03 filing 8-K/A items 9.01
- 2025-07-03 insider First Form 3/4/5 on record for Smith Andrew Alasdair (Chief Operating Officer)
- 2025-07-01 filing UPLOAD
- 2025-06-30 filing ARS
- 2025-06-30 filing Proxy statement
- 2025-06-30 filing 424B3
- 2025-06-30 filing 424B3
- 2025-06-30 filing 253G2
- 2025-06-30 filing 424B3
- 2025-06-30 filing 8-K items 1.01,8.01,9.01
- 2025-06-24 filing 253G2
- 2025-06-24 filing 424B3
- 2025-06-24 filing 424B3
- 2025-06-24 filing 424B3
- 2025-06-23 filing CORRESP
- 2025-06-23 filing PRER14A
- 2025-06-23 officer change 8-K items 5.02,8.01,9.01
- 2025-06-20 filing 424B3
- 2025-06-20 filing UPLOAD
- 2025-06-20 filing 424B3
- 2025-06-20 filing 253G2
- 2025-06-20 filing 424B3
- 2025-06-20 filing 8-K items 1.01,2.03,9.01
- 2025-06-13 filing PRE 14A
- 2025-06-06 filing 424B3
- 2025-06-06 filing 424B3
- 2025-06-06 filing 253G2
- 2025-06-06 filing 424B3
- 2025-06-05 filing 8-K items 4.01,9.01
- 2025-06-03 filing 424B3
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-19 (within 7 days) 424B3 filed (FORM 424B3)
- 2026-11-19 (within 7 days) 8-K filed: Item 3.01 delisting notice; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-16 (within 7 days) 424B3 filed (FORM 424B3)
- 2026-11-16 (within 7 days) 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 3.03 rights of holders modified; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-16 (within 7 days) 424B5 filed (FORM 424B5)
- 2026-11-09 (within 30 days) 425 filed (FORM 425)
- 2026-11-06 (within 30 days) 425 filed (FORM 425)
- 2026-11-06 (within 30 days) 424B3 filed (FORM 424B3)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:MDCX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1997296 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | MDCX / Nasdaq, Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 981778211 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001997296 | SEC EDGAR / IRS |
| CUSIP | 58471K202 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001997296 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$47,281,513 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 14:59 UTC | Report an error |
| Total assets (at 2025-12-31) | $10,061,377 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-19 14:59 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$67,554 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 14:59 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $8,705,218 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-19 14:59 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
| State of incorporation | A6 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
| Business address | 300 CONSHOHOCKEN STATE RD., SUITE 200, W. CONSHOHOCKEN, PA, 19428 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
| Exchanges | Nasdaq, Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 14:59 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$22,776,769 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 14:59 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $205,595 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 14:59 UTC | Report an error |
| Form D total offering amount (D/A filed 2024-07-08) | $11,017,500 | 2024-07-08 | D/A | as filed | 2026-11-19 14:59 UTC | Report an error |
| Form D total amount sold (D/A filed 2024-07-08) | $11,017,500 | 2024-07-08 | D/A | as filed | 2026-11-19 14:59 UTC | Report an error |
| Form D industry group | Other Health Care | 2024-07-08 | D/A | as filed | 2026-11-19 14:59 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2024-07-08 | D/A | as filed | 2026-11-19 14:59 UTC | Report an error |
| Form D date of first sale | 2024-05-03 | 2024-07-08 | D/A | as filed | 2026-11-19 14:59 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-06 · accession 0001062993-26-005803
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$15,181,335 | 3 months ended 2026-09-30 | 10-Q | 2026-11-06 | 0001062993-26-005803 | 2026-11-19 14:59 UTC | Report an error |
| Cash and cash equivalents | $5,019,755 | at 2026-09-30 | 10-Q | 2026-11-06 | 0001062993-26-005803 | 2026-11-19 14:59 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-19 Filing 424B3 filed (FORM 424B3)
- 2026-11-19 Filing 8-K filed: Item 3.01 delisting notice; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-16 Filing 424B3 filed (FORM 424B3)
- 2026-11-16 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 3.03 rights of holders modified; Item 8.01 other event; Item 9.01 exhibits
- 2026-11-16 Filing 424B5 filed (FORM 424B5)
- 2026-11-09 Filing 425 filed (FORM 425)
- 2026-11-06 Filing 425 filed (FORM 425)
- 2026-11-06 Filing 424B3 filed (FORM 424B3)
- 2026-11-06 Filing 10-Q filed (FORM 10-Q)
- 2026-11-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-04 Filing 425 filed (FORM 425)
- 2026-10-30 Filing DEF 14A filed (FORM DEF 14A)
- 2026-10-26 Filing 424B3 filed (FORM 424B3)
- 2026-10-23 Filing 8-K filed: Item 3.01 delisting notice; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-19 Filing PRE 14A filed (FORM PRE 14A)
- 2026-10-16 Filing 424B3 filed (FORM 424B3)
- 2026-10-16 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-10-07 Filing 424B3 filed (FORM 424B3)
- 2026-10-07 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 Filing 424B3 filed (FORM 424B3)
- 2026-09-14 Filing 8-K filed: Item 1.02 agreement terminated; Item 9.01 exhibits
- 2026-09-11 Filing 8-K filed: Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-09-03 Filing 424B3 filed (FORM 424B3)
- 2026-09-03 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-13 Filing 424B3 filed (FORM 424B3)
8-K item text, as filed (excerpts)
- 2026-11-19 8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
As previously disclosed in the Current Report on Form 8-K filed by Medicus Pharma Ltd. (the "Company") with the Securities and Exchange Commission (the "SEC") on May 27, 2026, on May 20, 2026, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its Market Value of Listed Securities had been below $35 million for the previous 30 consecutive business days and that the Company was therefore not in compliance with Nasdaq Listing Rule 5550(b)(2), and the Company was provided until November 16, 2026 to regain compliance or satisfy an alternative continued listing standard. On November 18, 2026, the… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-19 8-K Item 7.01, Regulation FD Disclosure
On November 19, 2026, the Company issued a press release regarding the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-19 8-K Item 8.01, Other Events
On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million set forth in Nasdaq Listing Rule 5550(b)(1), giving effect to the completion of the transactions described in the Company's Current Report on Form 8-K filed with the SEC on November 16, 2026. The Conditional Compliance Notice stated that the Company's compliance is… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-16 8-K Item 1.01, Entry into a Material Definitive Agreement
Exchange Agreement On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor"). Pursuant to the Exchange Agreement, $10.5 million in principal amount of the Company's Secured Promissory Note A-1, issued on May 27, 2026 in the original principal amount of $12,864,225 (the "A-1 Note"), was partitioned from the A-1 Note into a new note (the "Partitioned Note"), and the Investor exchanged the Partitioned Note for 105,000 non-convertible, non-voting preferred shares of the Company (the "Preferred Shares"), in a form authorized under the Company's current Articles of… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-16 8-K Item 3.02, Unregistered Sales of Equity Securities
The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Private Placements is incorporated into this Item 3.02 by reference. The Preferred Shares were issued to the Investor in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, or, alternatively, by Section 4(a)(2) of the Securities Act, and the Common Shares issued in the Private Placements were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-16 8-K Item 3.03, Material Modification to Rights of Security Holders
The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Preferred Shares is incorporated into this Item 3.03 by reference. the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-16 8-K Item 8.01, Other Events
The information contained in Items 1.01, 3.02 and 3.03 of this Current Report on Form 8-K is incorporated into this Item 8.01 by reference. In connection with the Offering, the Company is filing as Exhibit 5.1 the opinion of Bennett Jones LLP regarding the validity of the issuance of the Shares and the Pre-Funded Warrant Shares and as Exhibit 5.2 the opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP regarding the validity of the Pre-Funded Warrants, together with the related consents as Exhibits 23.1 and 23.2, each for incorporation by reference into the Registration Statement. Additionally, since the quarter ended September 30, 2026 and as of November 12, 2026, the Company has… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-11-04 8-K Item 7.01
Regulation FD Disclosure. On November 4, 2026, Medicus Pharma Ltd. (the "Company" or "Medicus") issued a press release announcing a non-binding letter of intent in connection with a potential business combination (the "Business Combination") of its wholly-owned subsidiary, Skinject, Inc. and an undisclosed special purpose acquisition company ("SPAC"). Furnished as Exhibits 99.1 and 99.2 hereto and incorporated by reference herein are press releases issued in connection with the proposed business combination and related matters. Important Information and Where To Find It This Current Report on Form 8-K is provided for informational purposes only and contains information with respect to a… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-10-23 8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On October 23, 2026, Medicus Pharma Ltd. (the "Company") received written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the $1.00 minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), and that the matter was now closed. The Compliance Notice supersedes the disclosure set forth in the following paragraph of this Item 3.01 regarding the Delisting Determination Letter (as defined below). For additional information regarding the Compliance Notice, see Item 8.01 of this Current Report on… the 8-K · retrieved 2026-11-19 14:59 UTC - 2026-10-23 8-K Item 8.01, Other Events
As described in Item 3.01 above, on October 23, 2026, the Company received the Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that Nasdaq had determined that for the last ten consecutive business days, from October 12, 2026 to October 23, 2026, the closing bid price of the Shares had been at $1.00 per Share or greater and that, accordingly, the Company had regained compliance with the Minimum Bid Price Requirement and that the matter was now closed. There can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement or Nasdaq's other continued listing requirements in the future. the 8-K · retrieved 2026-11-19 14:59 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Interchange Capital Partners, LLC | $718,376 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 2 | JANE STREET GROUP, LLC | $148,918 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 3 | XTX Topco Ltd | $108,612 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 4 | Sterling Investment Advisors, Ltd. | $44,630 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | $23,490 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 6 | May Hill Capital, LLC | $22,593 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $14,041 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 8 | STIFEL FINANCIAL CORP | $13,389 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 9 | JPMORGAN CHASE & CO | $12,498 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
| 10 | Wilmington Savings Fund Society, FSB | $11,435 | 2026-06-30 | SEC 13F filing | 2026-11-19 14:59 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1997296.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001997296. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.